NEWSLETTER
RSS
MOBILE
HELP
SHARE
Email Confirmation
Merck Has a Remedy
by Portfolio Staff
Oct 22 2007
Oct 22 2007
Drug giant raises forecast as earnings surge.
Last Trade:Change:
Summary:
A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative … View More
Richard T. Clark
Industry:
Healthcare
Biography:
Richard T. Clark, Chairman of the Board (since April 2007), President and Chief Executive Officer (since May 2005), President, … View More
The first big earnings report of the week was a positive one, as 
Merck announced a 62 percent increase in third quarter earnings. The company also raised its profit estimate for the year.
The drugmaker, which has been cutting costs in a turnaround effort amid a costly legal fight over the painkiller Vioxx, said revenue rose 12 percent in the third quarter, to $6.1 billion. Merck earned $1.5 billion, or 70 cents per share, compared with $941 million, or 43 cents per share, in the quarter a year earlier. Its earnings a year ago were reduced by $199.6 million in restructuring charges and by $598 million for legal costs related to Vioxx.
"Our third quarter results reflect the continued progress Merck is making to deliver on our strategy," said Merck's chief executiveRichard T. Clark.
The results were helped by its allergy drug Singular, which had sales of $1 billion in the quarter, up 17 percent.
Its cholesterol drugs, Vytorin and Zetia, which Merck has in a joint venture with Schering-Plough also did well, with sales for the two drugs combined rising 26 percent in the quarter.
Merck announced a 62 percent increase in third quarter earnings. The company also raised its profit estimate for the year. The drugmaker, which has been cutting costs in a turnaround effort amid a costly legal fight over the painkiller Vioxx, said revenue rose 12 percent in the third quarter, to $6.1 billion. Merck earned $1.5 billion, or 70 cents per share, compared with $941 million, or 43 cents per share, in the quarter a year earlier. Its earnings a year ago were reduced by $199.6 million in restructuring charges and by $598 million for legal costs related to Vioxx.
"Our third quarter results reflect the continued progress Merck is making to deliver on our strategy," said Merck's chief executive
Richard T. Clark.The results were helped by its allergy drug Singular, which had sales of $1 billion in the quarter, up 17 percent.
Its cholesterol drugs, Vytorin and Zetia, which Merck has in a joint venture with Schering-Plough also did well, with sales for the two drugs combined rising 26 percent in the quarter.
Mobile